2. Disease Areas
  3. Inflammation or Immune System Disease Metabolic or Endocrine Disease
  4. Autoimmune Disease Glucose Metabolism
  5. Type 1 Diabetes

Type 1 Diabetes

Type 1 diabetes mellitus is an autoimmune disorder characterized by the destruction of pancreatic beta cells, resulting in absolute insulin deficiency and consequent hyperglycemia. It typically presents with symptoms such as polyuria, polydipsia, weight loss, fatigue, and blurred vision. Without exogenous insulin therapy, patients are at risk for life-threatening complications including diabetic ketoacidosis and long-term microvascular and macrovascular damage affecting the eyes, kidneys, nerves, and blood vessels. Lifelong insulin replacement is essential for survival and metabolic control.

Type 1 Diabetes (53):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P9917
    Tocilizumab 375823-41-9 99.67%
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
    Tocilizumab
  • HY-P99222
    Teplizumab 876387-05-2 99.0%
    Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.
    Teplizumab
  • HY-P990228
    Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) 99.08%
    Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-10R/CD210. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) blocks IL-10R signaling. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) can be used for the researches of cancer, infection and metabolic disease, such as diabetes and malaria.
    Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)
  • HY-172371
    Hypoxystat 2414508-40-8 99.28%
    Hypoxystat is an orally active hypoxia mimetic. HypoxyStat increases Hemoglobin’s oxygen affinity, limiting oxygen offloading to the tissues and inducing local tissue hypoxia. Hypoxystat reduces Iba1+ cells. HypoxyStat causes systemic hypoxia. Hypoxystat effectively rescues hyperglycemia in mouse models of type 1 and type 2 diabetes. HypoxyStat not only extends lifespan but also rescues key neuropathological and behavioral deficits in the premier mouse model of Leigh syndrome.
    Hypoxystat
  • HY-P99646
    Golocdacimab 2418540-63-1 99.11%
    Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus.
    Golocdacimab
  • HY-183960
    BPyO-34 890601-68-0
    BPyO-34 is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 0.52 μM against human targets. BPyO-34 inhibits the activity of ASK1 in in vitro kinase assays. BPyO-34 can be used in research related to various diseases such as diabetes and cancer.
    BPyO-34
  • HY-181335
    SKL1223 3093938-66-7
    SKL1223 is an orally effective thioredoxin-interacting protein (TXNIP) inhibitor with an IC50 of 0.64 µM. SKL1223 interacts with the E-box region of the TXNIP promoter to inhibit TXNIP transcription and related signaling pathways. SKL1223 reduces hepatic glucose output. SKL1223 exerts hypoglycemic effects by regulating the action of glucagon, and modulates blood glucose levels in Streptozotocin (HY-13753)-induced and obesity-induced diabetic mice. SKL1223 can be used in the research of type 1 diabetes and type 2 diabetes.
    SKL1223
  • HY-P11664
    Anvoglutide 3091730-40-1
    Anvoglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with antidiabetic and obesity effects.
    Anvoglutide
  • HY-109555
    Insulin glulisine 207748-29-6
    Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes.
    Insulin glulisine
  • HY-P2917
    Glycerol kinase, microorganism 9030-66-4 98.00%
    Glycerol kinase, microorganism (GyK) acts as a NR4A1 inhibitor with enzymatic activity. It directly binds to and inhibits the transcription factor NR4A1, thereby negatively regulating hepatic gluconeogenesis and reducing blood glucose levels. Glycerol kinase, microorganism positively regulates UCP1 expression via partial dependence on the β-adrenergic receptor-cAMP-CREB pathway, promotes browning of white adipose tissue and thermogenesis, and further modulates intracellular fatty acid composition and energy metabolism. In diabetic mouse models, overexpression of Glycerol kinase effectively antagonizes NR4A1-induced hyperglycemia, demonstrating potential for improving glucose homeostasis. Glycerol kinase, microorganism can be used for studies on diabetes and obesity.
    Glycerol kinase, microorganism
  • HY-P1856
    Proinsulin C-peptide (human) 33017-11-7 99.54%
    Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions.
    Proinsulin C-peptide (human)
  • HY-W002016
    Phthalazine 253-52-1 99.98%
    Phthalazine is a chemical scaffold. Phthalazine derivatives act as VEGFR-2 inhibitors, PARP-1 inhibitors, and anticancer agents. The complex of phthalazine with silver exhibits broad-spectrum antibacterial and antifungal activities against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa PAO1, and Candida albicans. Phthalazine derivatives possess potent vasodilatory activity. Phthalazine can be used in research related to colon adenocarcinoma, breast cancer, hypertension, diabetes, and microbial infections.
    Phthalazine
  • HY-164774
    (4S)-GLP-1 receptor agonist 14 2758659-09-3 99.62%
    (4S)-GLP-1 receptor agonist 14 is a potent and orally active GLP-1 receptor agonist with an EC50 ≤ 20 nM. (4S)-GLP-1 receptor agonist 14 can be used for research on diabetes, obesity, metabolic diseases, cardiovascular diseases, liver diseases, nonalcoholic steatohepatitis (NASH), and other diseases associated with GLP-1 receptor.
    (4S)-GLP-1 receptor agonist 14
  • HY-135783
    AT 1001 1314801-63-2 99.94%
    AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease.
    AT 1001
  • HY-107586
    Demethylasterriquinone B1 78860-34-1 98.10%
    Demethylasterriquinone B1 (DAQ B1; L-783281) is an orally active insulin receptor (insulin receptor) agonist and AKT activator. By activating AKT, Demethylasterriquinone B1 upregulates the expression and activity of eNOS to increase NO production, while downregulating the expression of the NADPH oxidase subunit p22phox to reduce oxidative stress and improve vascular endothelial dysfunction in hypertensive rats. Demethylasterriquinone B1 combind with an AKT inhibitor targets the insulin signaling pathway to activate two antiviral pathways, RNA interference and JAK/STAT, in mosquitoes, thereby reducing Zika virus infection.
    Demethylasterriquinone B1
  • HY-P2914
    Carnitine acetyltransferase 9029-90-7
    Carnitine acetyltransferase is a mitochondrial matrix enzyme that catalyzes the interconversion of Acetyl-CoA and Acetylcarnitine (HY-126358). Carnitine acetyltransferase functions as a positive regulator of total body glucose tolerance and muscle activity of pyruvate dehydrogenase. Carnitine acetyltransferase is responsible for mitochondrial acetyl-CoA balance and regulation of fatty acid oxidation by utilizing short- and medium- chain fatty acids and their corresponding acylcarnitines as substrates. Carnitine acetyltransferase plays a crucial role in regulating glucose homeostasis. Carnitine acetyltransferase can be utilized in the research of aging, obesity, and diabetes.
    Carnitine acetyltransferase
  • HY-N0887
    Isoastragaloside I 84676-88-0 99.49%
    Isoastragaloside I is a natural compound found in Astragalus membranaceus, with oral activity and multiple biological activities such as anti-inflammatory and antioxidant properties. Isoastragaloside I inhibits Akt, NF-κB, MAPKs and PI3K, enhances the activity of hepatic FXR, regulates the TGF-β/Smads signaling pathway, and upregulates antioxidant molecules downstream of Nrf2. Isoastragaloside I inhibits the expression of NO, TNF-α, iNOS, COX-2, IL-1β and VCAM-1, and reduces intracellular ROS levels. Isoastragaloside I attenuates blood-brain barrier disruption, restores intestinal barrier function, increases β-cell mass, improves glucose homeostasis, and elevates circulating adiponectin levels. Isoastragaloside I can be used for the study of neuroinflammation-related neurodegenerative diseases, cholestatic liver disease, and diabetes.
    Isoastragaloside I
  • HY-B2193A
    α-Amylase, Human Saliva 9000-90-2
    α-Amylase, Human Saliva (1,4-alpha-D-Glucan-glucanohydrolase) is a hydrolase enzyme that can be isolated from human saliva. α-Amylase, Human Saliva catalyses the hydrolysis of internal α-1, 4-glycosidic linkages in starch to yield products like glucose and maltose. α-Amylase, Human Saliva can be used in life science research.
    α-Amylase, Human Saliva
  • HY-B1451
    Imidapril hydrochloride 89396-94-1 99.91%
    Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions.
    Imidapril hydrochloride
  • HY-135893
    SGK1-IN-2 1426214-64-3 98.36%
    SGK1-IN-2 (Compound 14h) is a selective, ATP-competitive SGK1 inhibitor, with an IC50 of 0.005 μM at 10 μM ATP and an IC50 of 0.025 μM at 500 μM ATP. SGK1-IN-2 can be used in studies of cancer, hypertension and diabetes.
    SGK1-IN-2